AIM ImmunoTech Inc

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AIM ImmunoTech reports promising clinical progress and financial stability

AIM ImmunoTech demonstrated strong clinical progress and financial stability, positioning the company well for future growth and potential partnerships.
While facing regulatory and operational challenges, the company's focus on expanding Ampligen's therapeutic applications and medical expertise presents significant opportunities for advancement.
Investors should monitor AIM ImmunoTech's continued progress in clinical trials and regulatory interactions, as positive outcomes could drive value creation and market expansion.

AIM ImmunoTech reports positive clinical progress and solid financial standing

AIM ImmunoTech's Q2 2024 Earnings Call highlighted significant progress in clinical trials for Ampligen, particularly in oncology indications.
Financially, the company maintains a solid cash position and continues to manage expenses to support ongoing operations and future milestones.
While facing challenges in trial design and cost management, AIM ImmunoTech remains well-positioned to capitalize on opportunities for growth and partnership.

AIM ImmunoTech advances Ampligen with positive clinical data amid challenges

AIM ImmunoTech's Q3 showcased progress in Ampligen's development, with promising data supporting its therapeutic potential. While facing financial challenges, the company is focused on leveraging opportunities for collaborations and commercialization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Year marked by noteworthy operational execution and clinical development progress across pipeline

AIM ImmunoTech Issues Letter to Stockholders

Ongoing efforts to open additional clinical sites for recruitment at premier cancer centers across the U.S. and Europe are in progress to facilitate patient enrollment and dosing Ongoing efforts to open additional clinical sites for recruitment at premier cancer centers across the U.S. and Europe are in progress to facilitate patient enrollment and dosing

AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients

OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced it will participate in an event hosted by Solve M.E. Diagnostics and The Biotechnology Innovation Organization (BIO) titled, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?,” being held virtually on Tuesday, February 21, 2023, from 10:00 AM – 1:00 PM PT.

AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?

AstraZeneca

AIM ImmunoTech Inc (NYSE:AIM) (AIM) announced that it has entered into an external sponsored collaborative clinical research agreement with AstraZeneca and Erasmus Medical Center in the Netherlands that will evaluate the potential of AIM's Ampligen (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) for the treatment of pancreatic cancer.  Ampligen is AIM's dsRNA drug currently being developed for globally important cancers.

AIM ImmunoTech shares rise on news of pancreatic cancer research partnership with AstraZeneca and Erasmus Medical Center

Calyxt

Tritium DCFC Ltd

PLBY Group

SciSparc Ltd

Penny stocks to watch with news that are turning heads in the stock market this week. The post 5 Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch After Big News This Week

Research collaboration will evaluate the potential of AIM's Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) for the treatment of pancreatic cancer Research collaboration will evaluate the potential of AIM's Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) for the treatment of pancreatic cancer

AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

AIM ImmunoTech Inc (NYSE:AIM) has announced that the Netherlands Patent Office has granted the company a utility patent covering rugged dsRNA, a double-stranded RNA product related to its lead candidate Ampligen (rintatolimod), which claims cover, among other aspects, compositions, and compositions for use in the prevention or treatment of COVID-19.  The new patent broadens AIM's existing portfolio for COVID-19 treatments to include rugged dsRNA, the company said.

AIM ImmunoTech broadens patent portfolio with new Netherlands utility patent

OCALA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus— today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted a utility patent covering rugged dsRNA, a double-stranded RNA product related to Ampligen® (rintatolimod), which claims cover, among other aspects, compositions and compositions for use in the prevention or treatment of COVID-19. The new patent broadens AIM's existing portfolio for COVID-19 treatments to include rugged dsRNA.

AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention

Live video webcast on Wednesday, January 18th at 11:00 AM ET Live video webcast on Wednesday, January 18th at 11:00 AM ET

AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event'

AIM ImmunoTech Inc (NYSE:AIM) has announced the promotion of Christopher McAleer from the company's deputy scientific officer to the position of scientific officer. The immuno-pharma firm said McAleer is an accomplished scientist with a diverse range of skills from general wet lab technique to company-wide operations management.

AIM ImmunoTech promotes Christopher McAleer to the role of scientific officer

Accomplished scientist with a diverse range of skills from general wet lab technique to company-wide operations management Accomplished scientist with a diverse range of skills from general wet lab technique to company-wide operations management

AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer

AIM ImmunoTech Inc (NYSE:AIM) has reported positive safety, tolerability, and biological activity data from a Phase 1 study involving the intranasal administration of its lead product Ampligen (rintatolimod) in healthy subjects. Ampligen is an immuno-modulator with broad-spectrum activity being developed by AIM for globally important cancers, viral diseases and disorders of the immune system.

AIM ImmunoTech reports positive safety, tolerability, and biological activity data from Phase 1 Ampligen study

Intranasal administration of Ampligen demonstrated to be well-tolerated

AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) --  AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

AIM ImmunoTech Inc (NYSE:AIM) said it ended the third quarter of 2022 with cash and cash equivalents of $36.7 million, down from $48.3 million at the end of December 2021, but expected to fund operations through to the end of 2023. The Ocala, Florida-based company said research and development expenses for the three months ended September 30, 2022, were $1.4 million, compared to $2 million for the same period in 2021.

AIM ImmunoTech says cash position expected to fund operations through end of 2023

– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones

AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update

AIM ImmunoTech Inc (NYSE:AIM) has revealed positive data evaluating Ampligen (rintatolimod) as a component of a regimen for the treatment of early-stage triple negative breast cancer. Led by by Roswell Park Comprehensive Cancer Center medical oncologist Dr Shipra Gandhi, the data will be presented in a poster presentation at the Society for Immunotherapy of Cancer 37th annual meeting being held virtually and in Boston, Massachusetts from November 8 to 12, 2022.

AIM ImmunoTech shows positive results using Ampligen in treating triple negative breast cancer

– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting

AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer

Aimia, Inc. (OTCPK:AIMFF) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Albert Matousek - Head, IR & Communications Phil Mittleman - CEO Michael Lehmann - President Steve Leonard - CFO Conference Call Participants Surinder Thind - Jefferies Brian Morrison - TD Securities Operator Good morning, ladies and gentlemen, and welcome to the Aimia, Inc. Third Quarter 2022 Results Conference Call. At this time, all lines are in listen-only mode and following the presentation we will conduct a question-and-answer session.

Aimia, Inc. (AIMFF) Q3 2022 Earnings Call Transcript

AIM ImmunoTech Inc (NYSE:AIM) said it will add two directors to its board to bring diversity and additional biotechnology commercialization experience. AIM ImmunoTech also said its board compensation committee will engage an independent compensation consultant to evaluate the compensation plans currently in place for company executives.

AIM ImmunoTech to add board members, review executive salaries; highlights clinical advances in past year

AIM ImmunoTech Announces Corporate Governance Enhancements

AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting

AIM ImmunoTech Inc (NYSE:AIM) announced that its dsRNA product candidate Ampligen (rintatolimod) has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of Ebola virus disease. The company said it was developing Ampligen for globally important cancers, viral diseases, and disorders of the immune system.

AIM ImmunoTech's product candidate Ampligen granted FDA Orphan Drug Designation for treatment of Ebola

Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune system

AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

AIM ImmunoTech Inc (NYSE:AIM) said the Delaware Court of Chancery has denied an activist investor's bid to put two nominees on its board during the November 3 annual meeting of shareholders. In its decision, the court denied Jonathan Jorgl's motion for a mandatory preliminary injunction that sought to require the AIM board of directors to accept his director nominations and include his nominees on a universal proxy card.

News for AIM ImmunoTech Inc Stock (AIM)